364 related articles for article (PubMed ID: 33948771)
1. Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3.
Cristea S; Krekels EHJ; Allegaert K; De Paepe P; de Jaeger A; De Cock P; Knibbe CAJ
AAPS J; 2021 May; 23(3):65. PubMed ID: 33948771
[TBL] [Abstract][Full Text] [Related]
2. The Influence of Drug Properties and Ontogeny of Transporters on Pediatric Renal Clearance through Glomerular Filtration and Active Secretion: a Simulation-Based Study.
Cristea S; Krekels EHJ; Rostami-Hodjegan A; Allegaert K; Knibbe CAJ
AAPS J; 2020 Jun; 22(4):87. PubMed ID: 32566984
[TBL] [Abstract][Full Text] [Related]
3. Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling.
Dubinsky S; Malik P; Hajducek DM; Edginton A
Clin Pharmacokinet; 2022 Jul; 61(7):997-1012. PubMed ID: 35508593
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach.
Mathialagan S; Piotrowski MA; Tess DA; Feng B; Litchfield J; Varma MV
Drug Metab Dispos; 2017 Apr; 45(4):409-417. PubMed ID: 28179375
[TBL] [Abstract][Full Text] [Related]
5. Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans.
Tsuruya Y; Kato K; Sano Y; Imamura Y; Maeda K; Kumagai Y; Sugiyama Y; Kusuhara H
Drug Metab Dispos; 2016 Dec; 44(12):1925-1933. PubMed ID: 27638508
[TBL] [Abstract][Full Text] [Related]
6. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.
Komazawa H; Yamaguchi H; Hidaka K; Ogura J; Kobayashi M; Iseki K
J Pharm Sci; 2013 Mar; 102(3):1086-94. PubMed ID: 23280877
[TBL] [Abstract][Full Text] [Related]
7. Ontogeny of expression of organic anion transporters 1 and 3 in ovine fetal and neonatal kidney.
Wood CE; Cousins R; Zhang D; Keller-Wood M
Exp Biol Med (Maywood); 2005 Oct; 230(9):668-73. PubMed ID: 16179735
[TBL] [Abstract][Full Text] [Related]
8. Identification and Quantitative Assessment of Uremic Solutes as Inhibitors of Renal Organic Anion Transporters, OAT1 and OAT3.
Hsueh CH; Yoshida K; Zhao P; Meyer TW; Zhang L; Huang SM; Giacomini KM
Mol Pharm; 2016 Sep; 13(9):3130-40. PubMed ID: 27467266
[TBL] [Abstract][Full Text] [Related]
9. Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide.
Yaro P; Nie J; Xu M; Zeng K; He H; Yao J; Wang R; Zeng S
J Ethnopharmacol; 2019 Oct; 243():112098. PubMed ID: 31325605
[TBL] [Abstract][Full Text] [Related]
10. Oat1/3 restoration protects against renal damage after ischemic AKI.
Schneider R; Meusel M; Betz B; Held C; Möller-Ehrlich K; Büttner-Herold M; Wanner C; Gekle M; Sauvant C
Am J Physiol Renal Physiol; 2015 Feb; 308(3):F198-208. PubMed ID: 25391897
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation.
Commander SJ; Wu H; Boakye-Agyeman F; Melloni C; Hornik CD; Zimmerman K; Al-Uzri A; Mendley SR; Harper B; Cohen-Wolkowiez M; Hornik CP;
J Clin Pharmacol; 2021 Mar; 61(3):368-377. PubMed ID: 33029806
[TBL] [Abstract][Full Text] [Related]
12. Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically-Based Pharmacokinetic Modeling and Dose Adjustment.
Tan SPF; Scotcher D; Rostami-Hodjegan A; Galetin A
Clin Pharmacol Ther; 2022 Sep; 112(3):643-652. PubMed ID: 35569107
[TBL] [Abstract][Full Text] [Related]
13. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K).
Kikuchi R; Lao Y; Bow DA; Chiou WJ; Andracki ME; Carr RA; Voorman RL; De Morais SM
J Pharm Sci; 2013 Dec; 102(12):4426-32. PubMed ID: 24122511
[TBL] [Abstract][Full Text] [Related]
14. Low-dose indomethacin after ischemic acute kidney injury prevents downregulation of Oat1/3 and improves renal outcome.
Schneider R; Meusel M; Renker S; Bauer C; Holzinger H; Roeder M; Wanner C; Gekle M; Sauvant C
Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1614-21. PubMed ID: 19794109
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of organic anion transporters OAT1 and OAT3 correlates with impaired secretion of para-aminohippurate after ischemic acute renal failure in rats.
Schneider R; Sauvant C; Betz B; Otremba M; Fischer D; Holzinger H; Wanner C; Galle J; Gekle M
Am J Physiol Renal Physiol; 2007 May; 292(5):F1599-605. PubMed ID: 17244891
[TBL] [Abstract][Full Text] [Related]
16. Effects of 1α,25-dihydroxyvitamin D3 , the natural vitamin D receptor ligand, on the pharmacokinetics of cefdinir and cefadroxil, organic anion transporter substrates, in rat.
Kim YC; Kim IB; Noh CK; Quach HP; Yoon IS; Chow ECY; Kim M; Jin HE; Cho KH; Chung SJ; Pang KS; Maeng HJ
J Pharm Sci; 2014 Nov; 103(11):3793-3805. PubMed ID: 25266751
[TBL] [Abstract][Full Text] [Related]
17. Drug Elimination Alteration in Acute Lymphoblastic Leukemia Mediated by Renal Transporters and Glomerular Filtration.
Zhou Y; Du B; Kan M; Chen S; Tang BH; Nie AQ; Ye PP; Shi HY; Hao GX; Guo XL; Han QJ; Zheng Y; Zhao W
Pharm Res; 2020 Aug; 37(8):158. PubMed ID: 32743772
[TBL] [Abstract][Full Text] [Related]
18. Differential Interaction of Dantrolene, Glafenine, Nalidixic Acid, and Prazosin with Human Organic Anion Transporters 1 and 3.
Burckhardt BC; Henjakovic M; Hagos Y; Burckhardt G
J Pharmacol Exp Ther; 2017 Sep; 362(3):450-458. PubMed ID: 28630284
[TBL] [Abstract][Full Text] [Related]
19. Differential interactions of the β-lactam cloxacillin with human renal organic anion transporters (OATs).
Lalanne S; Le Vée M; Lemaitre F; Le Corre P; Verdier MC; Fardel O
Fundam Clin Pharmacol; 2020 Aug; 34(4):476-483. PubMed ID: 32100322
[TBL] [Abstract][Full Text] [Related]
20. Understanding adefovir pharmacokinetics as a component of a transporter phenotyping cocktail.
Dong Q; Chen C; Taubert M; Bilal M; Kinzig M; Sörgel F; Scherf-Clavel O; Fuhr U; Dokos C
Eur J Clin Pharmacol; 2024 Jul; 80(7):1069-1078. PubMed ID: 38546841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
